Cefoxitinにかんする臨床的研究 (Cefoxitin論文特集号)

概要

論文の詳細を見る
Cefoxitin (CFX), a new semisynthetic cephamycin antibiotic, was studied as to its antibacterial activity, absorption, excretion and clinical effect, and following results were obtained: 1) Antibacterial activity Susceptibility to CFX was distributed among 0.39>100μg/ml with E. coli, 40 of 50 strains were inhibited at 6. 25ug/ml or less, 0.78-3.14μg/ml with Proteus mirabilis, 3.13->100μg/ml with Klebsiella pneumoniae, 36 of 50 strains were inhibited at 6.25μg/ml or less, and 12.5->100μg/ml with Serratia marcescens. Antibacterial activity of CFX against Gram-negative bacteria was similar to that of cefazolin. 2) Serum levels and urinary excretion The Peak of serum level in healthy adult was 50μ/ml at the end of a drip infusion of 2.0g dose in 250ml, thereafter the serum level rapidly decreased, showing 3.5μg/ml after 2 hours. The serum half life was 0.78 hour, and urinary recovery within 7 hours was 67.2%. 3) Clinical results CFX was clinically applied to 8 cases with bacterial infections, including 2 cases of cholecystitis and 6 cases of urinary tract infections, and the results obtained were good in 6 cases and poor in 2 cases. No marked side effects were observed.
公益社団法人日本化学療法学会の論文